{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:17:12Z","timestamp":1780377432514,"version":"3.54.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Newly diagnosed multiple myeloma patients have many available treatment options. While lenalidomide, bortezomib, and dexamethasone (RVD) is the preferred initial treatment for many patients, several other agents may provide similar efficacy with less toxicity and improved ease of administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated the safety and efficacy of the all-oral regimen of ixazomib, cyclophosphamide, and dexamethasone with the use of metronomic cyclophosphamide dosing in the treatment of patients with newly diagnosed multiple myeloma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study was stopped prior to planned enrollment due to slow recruitment, with 12 patients available for final analysis. The overall response rate was 58.3% with 2 patients achieving a very good partial response (16.7%) and 5 patients achieving a partial response (41.7%). Median progression-free survival was 16 months, and median overall survival was 43 months. There were no episodes of grade 3 or greater peripheral neuropathy. Grade 3 or greater dermatologic toxicity was experienced in 50% of patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although limited enrollment prevented full efficacy evaluation, our data do not support further study of metronomic cyclophosphamide in combination with ixazomib and dexamethasone in the treatment of newly diagnosed multiple myeloma. The activity of this regimen in the relapsed\/refractory setting requires further study (ClinicalTrials.gov Identifier: NCT02412228).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad017","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T22:36:31Z","timestamp":1679438191000},"page":"462-e303","source":"Crossref","is-referenced-by-count":3,"title":["Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-4499","authenticated-orcid":false,"given":"Ari","family":"Pelcovits","sequence":"first","affiliation":[{"name":"Department of Medicine, Alpert Medical School of Brown University , Providence, RI , USA"},{"name":"Division of Hematology-Oncology, Rhode Island Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alpert Medical School of Brown University , Providence, RI , USA"},{"name":"Division of Hematology-Oncology, Rhode Island Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Reagan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alpert Medical School of Brown University , Providence, RI , USA"},{"name":"Division of Hematology-Oncology, Rhode Island Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alpert Medical School of Brown University , Providence, RI , USA"},{"name":"Division of Hematology-Oncology, Rhode Island Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie","family":"Rosati","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Rhode Island Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Wood","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Rhode Island Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlee","family":"Sturtevant","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Rhode Island Hospital , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S","family":"Winer","sequence":"additional","affiliation":[{"name":"Division of Adult Leukemia, Dana-Farber Cancer Center , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"21","key":"2023050815243519200_CIT0001","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2023050815243519200_CIT0002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsred multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Brit J Haematol"},{"issue":"1","key":"2023050815243519200_CIT0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2015.01.008","article-title":"Metronomic chemotherapy forom rationale to clinical studies: a dream or reality?","volume":"95","author":"Gnoni","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"17","key":"2023050815243519200_CIT0004","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"2023050815243519200_CIT0005","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Working Group Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"2023050815243519200_CIT0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos","year":"2019","journal-title":"Eur J Cancer"},{"issue":"26","key":"2023050815243519200_CIT0007","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"10068","key":"2023050815243519200_CIT0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"2023050815243519200_CIT0009","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2023050815243519200_CIT0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"16","key":"2023050815243519200_CIT0011","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2023050815243519200_CIT0012","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2023050815243519200_CIT0013","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2023050815243519200_CIT0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjh.13004","article-title":"Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma","volume":"167","author":"Reeder","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"2023050815243519200_CIT0015","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"22","key":"2023050815243519200_CIT0016","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/462\/50247554\/oyad017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/462\/50247554\/oyad017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:24:39Z","timestamp":1683563079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/462\/7081548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,3]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad017","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,3,3]]}}}